Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Pharma Holdings Seeks Approval of Generic Hypertension Drug

publication date: Jan 22, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Pharma Holdings reported that its clinical trials for a generic version of Candesartan, an anti-hypertension drug, have been completed successfully, and China Pharma has submitted a generic drug production application for Candesartan to the SFDA. Candesartan Cilexetil is a prodrug of Candesartan, which allows the product to be administered orally and also means that it remains effective for a full day. More details...

Stock Symbol: (NYSE: CPHI)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors